Effects of GH assay standardization on evaluation of treatment outcomes for acromegaly in Japan

Endocrine Journal

Makiko Kurimoto¹  Izumi Fukuda¹  Kazue Takano¹  Naomi Hizuka¹  Satoshi Tanaka¹  Yu Yamakado¹  Toko Muraoka¹ 

[1] Department of Medicine II, Tokyo Women’s Medical University, Tokyo 162-8666, Japan

关键词: Acromegaly;    GH standardization;    Diabetes mellitus;   

DOI  :  10.1507/endocrj.K11E-099

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(11)Cited-By(1)In Japan, the growth hormone (GH) assay has been standardized since April 2005 through use of a uniform recombinant human GH (rhGH) standard.Since then, GH values measured using the rhGH standard have been approximately 40% lower than previous values measured using kit standards based on the WHO standards for hGH of pituitary origin.However, the Japanese criteria for evaluating treatment outcomes for acromegaly have remained the same: a nadir GH during a 75 g OGTT <1 μg/L is considered cured, 1≤GH<2.5μg/L is considered inadequately controlled, and ≥2.5 μg/L is considered poorly controlled, instead of these levels were lowered to 60%, i.e. from 1 to 0.6 μg/L for cured and from 2.5 to 1.5μg/L for inadequately controlled (termed as “newly proposed criteria” in this study).We investigated the effects of standardization of the GH assay on the evaluation of post-surgical disease activity in 50 patients with acromegaly (M/F 19/31, 21-72 yr.).Post-surgical nadir GH levels during OGTT were positively correlated with the IGF-I SD score 3 months after TSS.Five of 6 patients whose post-surgical nadir GH levels ranged between 0.6 and 1 μg/L had normal serum IGF-I levels 3 months after TSS.Rates of improvement in glucose metabolism did not differ when patients were classified based on the present criteria vs. the newly proposed criteria.In conclusion, the current Japanese remission criteria for acromegaly still accurately reflect post-surgical disease activity in most patients, though long-term observation is still required.

【 授权许可】

Unknown